VAERS Explorer
Back to explore

Report #2861132

Received Sep 24, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
83 yrs
State
—
Recovered
Unknown
Vaccinated
—
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
COVID19COVID19 (COVID19 (MODERNA))MODERNAUNK—IM

Symptoms (3)

Blood immunoglobulin AImmunoglobulinsNon-Hodgkin's lymphoma

Symptom narrative

Recurrent Non-Hodgkin lymphoma in the L3 region of the spine; This spontaneous case was reported by a consumer and describes the occurrence of NON-HODGKIN'S LYMPHOMA (Recurrent Non-Hodgkin lymphoma in the L3 region of the spine) in an 83-year-old male patient who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. Concurrent medical conditions included Non-Hodgkin's lymphoma (Patient reported a diagnosis of non-Hodgkin's lymphoma back in 2005.) since 2005. In 2023, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form. In 2023, the patient experienced NON-HODGKIN'S LYMPHOMA (Recurrent Non-Hodgkin lymphoma in the L3 region of the spine) (seriousness criterion medically significant). The patient was treated with Radiotherapy (radiation) for Non-Hodgkin's lymphoma. At the time of the report, NON-HODGKIN'S LYMPHOMA (Recurrent Non-Hodgkin lymphoma in the L3 region of the spine) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood immunoglobulin A: subclinical IgA levels. On an unknown date, Immunoglobulins: all other immunoglobulin levels remain normal. The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) was unknown. No concomitant medications were reported. It was reported that patient received many Moderna COVID-19 vaccines and specifically mentioned receiving a shot in 2023, prior to the recurrence of non-Hodgkin lymphoma in the L3 region of the spine, which was treated with radiation in 2023. It was reported that the patient was being immunocompromised, though not severely, as a result of cancer treatment. This had led to subclinical IgA levels, while all other immunoglobulin levels remained normal. No specific treatment medications were reported.; Reporter's Comments: Medical history of Non-Hodgkin´s lymphoma remains as a risk factor for the event. The benefit-risk relationship of product is not affected by this report.

Current illness

Non-Hodgkin's lymphoma (Patient reported a diagnosis of non-Hodgkin's lymphoma back in 2005.)

Lab data

Test Name: IgA levels; Result Unstructured Data: subclinical IgA levels; Test Name: immunoglobulin; Result Unstructured Data: all other immunoglobulin levels remain normal